| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Linaclotide |
| Brand | Constella® |
| Indication | For the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults. |
| Assessment Process | |
| Rapid review commissioned | 28/05/2013 |
| Rapid review completed | 28/06/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Linaclotide (Constella®) is to be reimbursed under the Community Drugs Schemes subject to conditions.